Retinal Physician – Artificial Intelligence as a Disruptor to AMD Diagnosis
Companies plan for an expanded role for AI in retina therapies.
Related Articles
Roche, Ainnova Partner on Vision Screening Program
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Ocular Therapeutix Completes Enrollment
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Leveraging Social Media to Enhance Your Career
Used correctly, Facebook, Instagram, and other social platforms can be useful tools to educate patients, share expertise, and grow your practice.
Coding Q&A: Medicare as a Secondary Payer
In certain cases, health care providers must determine whether Medicare is the primary or secondary payer to ensure correct billing and compliance with regulations.
Best Practices Regarding Choroidal Nevus Follow-up
Distinguishing between choroidal nevus and lesions concerning for choroidal melanoma is an important skill for all ophthalmologists, because early referral and treatment of choroidal melanoma…
Ocugen Reports Preliminary Data
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
Clinical Trial Update November/December 2024
Access Retinal Physician’s listing of all active clinical trials in AMD, DME, RVO, and uveitis.
Cencora to Acquire RCA
PentaVision is an independent company dedicated to eye care professionals. More about our magazines, newsletters, conferences, education and other services at pentavisionmedia.com.
The Pathology of Stargardt Disease and Future Treatment Horizons
Understanding the clinical presentation and underlying pathology of Stargardt disease is crucial for identifying patients as well as developing and offering effective treatments. Ongoing research…